Long-Term Data Show Sustained Benefit of Siponimod for Secondary Progressive MS
April 22nd 2020Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.